CVCharlotte E. Vollenbrock

Charlotte E. Vollenbrock

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Charlotte E. Vollenbrock has a total of 56 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Association of genetic variation with age at diagnosis in type 1 diabetes

    by Charlotte E Vollenbrock, Delnaz Roshandel, Kristine E Lee, Barbara E Klein, Dick Mul, Melanie M van der Klauw, Cornelis J Tack, Marian Rewers, Janet K Snell-Bergeon, Tina Costacou, et al.

    Introduction: Type 1 diabetes is an autoimmune disease with a strong genetic basis. The aim of this study was to identify additional single-nucleotide polymorphisms (SNPs) for type 1 diabetes age at diagnosis and to replicate previously identified loci. Research design and methods: Meta genome-wide association studies of age at diagnosis from eight cohorts (n=5910 in total) were performed in three models. Model 1 was age at diagnosis with no covariates. Model 2 was age at diagnosis adjusted for DR3/DR4 genotype categories. Model 3 was similar to model 2, including the most significant SNP from model 2 (coded additively). Models 1 and 2 were also performed for major histocompatibility complex (MHC) imputed data. In addition, we tested previously identified loci for age at diagnosis and type 1 diabetes risk for association with age at diagnosis in model 1. Results: In model 1, we identified a genome-wide significant locus (rs2856721, p=3.3×10 −11 ) in the MHC region whose effect was attenuated in model 2 (p=0.03). In model 2, we identified another locus in the MHC region, rs76730244, p=4.9×10 −9 , which was associated with age at diagnosis adjusted for DR3/DR4 genotypes. Model 3 and analysis of the MHC region did not reveal novel loci. Among 14 previously identified SNPs for age at diagnosis, 6 were confirmed; in addition, 11 out of 78 non-HLA loci for type 1 diabetes risk were associated with age at diagnosis. Conclusions: We identified rs76730244 in the MHC region for age at diagnosis of type 1 diabetes, which was independent of the HLA-DR3/DR4 genotype categories. We also confirmed 6 previously identified SNPs and showed that 11 non-HLA loci for type 1 diabetes risk are associated with age at diagnosis.


  • Open Access

    Cohort profile: the ‘Biomarkers of heterogeneity in type 1 diabetes’ study—a national prospective cohort study of clinical and metabolic phenotyping of individuals with long-standing type 1 diabetes in the Netherlands

    by Henk-Jan Aanstoot, Rita D M Varkevisser, Dick Mul, Pim Dekker, Erwin Birnie, Lianne S M Boesten, Michael P Brugts, Peter R van Dijk, Petronella H L M Duijvestijn, Sanjoy Dutta, et al.

    Purpose The ‘Biomarkers of heterogeneity in type 1 diabetes’ study cohort was set up to identify genetic, physiological and psychosocial factors explaining the observed heterogeneity in disease progression and the development of complications in people with long-standing type 1 diabetes (T1D). Participants Data and samples were collected in two subsets. A prospective cohort of 611 participants aged ≥16 years with ≥5 years T1D duration from four Dutch Diabetes clinics between 2016 and 2021 (median age 32 years; median diabetes duration 12 years; 59% female; mean glycated haemoglobin (HbA1c) 61 mmol/mol (7.7%); 61% on insulin pump; 23% on continuous glucose monitoring (CGM)). Physical assessments were performed, blood and urine samples were collected, and participants completed questionnaires. A subgroup of participants underwent mixed-meal tolerance tests (MMTTs) at baseline (n=169) and at 1-year follow-up (n=104). Genetic data and linkage to medical and administrative records were also available. A second cross-sectional cohort included participants with ≥35 years of T1D duration (currently n=160; median age 64 years; median diabetes duration 45 years; 45% female; mean HbA1c 58 mmol/mol (7.4%); 51% on insulin pump; 83% on CGM), recruited from five centres and measurements, samples and 5-year retrospective data were collected. Findings to date Stimulated residual C-peptide was detectable in an additional 10% of individuals compared with fasting residual C-peptide secretion. MMTT measurements at 90 min and 120 min showed good concordance with the MMTT total area under the curve. An overall decrease of C-peptide at 1-year follow-up was observed. Fasting residual C-peptide secretion is associated with a decreased risk of impaired awareness of hypoglycaemia. Future plans Research groups are invited to consider the use of these data and the sample collection. Future work will include additional hormones, beta-cell-directed autoimmunity, specific immune markers, microRNAs, metabolomics and gene expression data, combined with glucometrics, anthropometric and clinical data, and additional markers of residual beta-cell function. Trial registration number NCT04977635.


  • Open Access

    Cohort profile: the ‘Biomarkers of heterogeneity in type 1 diabetes’ study – a prospective cohort study of clinical and metabolic phenotyping of individuals with long-standing type 1 diabetes

    by Dick Mul, Rita D.M. Varkevisser, Henk-Jan Aanstoot, Pim Dekker, Erwin Birnie, Erik Boersma, Lianne S.M. Boesten, Michael P. Brugts, Peter R. van Dijk, Petronella H.L.M. Duijvestijn, et al.

    Purpose The ‘Biomarkers of heterogeneity in type 1 diabetes’ study cohort was set up to identify genetic, physiological and psychosocial factors explaining the observed heterogeneity in disease progression and the development of complications in people with long-standing type 1 diabetes (T1D). Data and samples are available for new studies and collaborations. Participants Data- and samples were collected in two subsets. 1) A prospective cohort of 611 participants aged ≥16 years with ≥5 years T1D duration was recruited from four Dutch Diabetes clinics between June 2016 and March 2021. At baseline and 1- and 2-year follow-up visits, physical assessments were performed, and blood and urine samples were collected. Participants completed questionnaires about diabetes-related problems, quality of life, neuropathy and impaired awareness of hypoglycaemia at baseline and at the last follow-up visit. A subgroup of participants underwent mixed-meal tolerance tests (MMTT) at baseline (n=169) and at 1-year follow-up (n=104). Genetic data and linkage to medical and administrative records were also available. 2) A second cross-sectional cohort, aiming to include 200 participants aged ≥18 years with ≥35 years T1D duration, was recruited from 7 centres, collecting measurements and samples plus 5-year retrospective data. Findings to date Fasting residual C-peptide secretion associated with decreased risk of impaired awareness of hypoglycaemia. Stimulated residual C-peptide was detectable in an additional 10% of individuals compared with fasting residual C-peptide secretion. MMTT measurements at 90 minutes and 120 minutes showed good concordance with the MMTT total area under the curve. An overall decrease of C-peptide at 1-year follow-up was observed. Future plans Research groups are invited to consider the use of this data and sample collection. Future work will include additional hormones, beta-cell-directed autoimmunity, specific immune markers, microRNA’s, metabolomics and gene expression data, combined with glucometrics, anthropometric/clinical data and additional markers of residual beta-cell function. Strengths - The Biomarker cohort is a large longitudinal prospective cohort study with three time points, collecting biosamples and clinical data from participants with well-established and long-standing type 1 diabetes (≥5 years). - A subgroup with detailed clinical data underwent MMTT tests at two timepoints allowing further residual beta-cell marker studies. - The Biomarker and Long-Term type 1 Diabetes cohorts represent a “real-world” population, also including participants from non-academic/-specialised centres. Limitations - Despite the fact that data and biosamples were collected from more than 600 participants, this number may be too low for (sub) stratification of the data (e.g. insulin delivery modality, different treating centres and therapies etc.). - In the prospective group there was a relatively high dropout rate of 25% after 2 years, largely affected by the Covid-19 outbreak.

  • Open Access

    Fasting and meal‐stimulated serum C‐peptide in long‐standing type 1 diabetes mellitus

    by Charlotte E. Vollenbrock, Dick Mul, Pim Dekker, Erwin Birnie, Martine M. C. de Vries‐Velraeds, Lianne Boesten, Joost Groen, Petronella H. L. M. Geelhoed‐Duijvestijn, Henk‐Jan Aanstoot, Bruce H. R. Wolffenbuttel

    Aims: This study aims to evaluate the stability of C‐peptide over time and to compare fasting C‐peptide and C‐peptide response after mixed‐meal tolerance test (MMTT) at T90 or T120 with C‐peptide area under the curve (AUC) in long‐standing type 1 diabetes.Methods: We included 607 type 1 diabetes individuals with diabetes duration >5 years. C‐peptide concentrations (ultrasensitive assay) were collected in the fasting state, and in a subpopulation after MMTT (T0, just prior to, T30‐T60‐T90‐T120, 30–120 min after ingestion of mixed‐meal) (n = 168). Fasting C‐peptide concentrations (in n = 535) at Year 0 and Year 1 were compared. The clinical determinants associated with residual C‐peptide secretion and the correspondence of C‐peptide at MMTT T90 / T120 and total AUC were assessed.Results: A total of 153 participants (25%) had detectable fasting serum C‐peptide (i.e ≥ 3.8 pmol/L). Fasting C‐peptide was significantly lower at Year 1 (p < 0.001, effect size = −0.16). Participants with higher fasting C‐peptide had a higher age at diagnosis and shorter disease duration and were less frequently insulin pump users. Overall, 109 of 168 (65%) participants had both non‐detectable fasting and post‐meal serum C‐peptide concentrations. The T90 and T120 C‐peptide values at MMTT were concordant with total AUC. In 17 (10%) individuals, C‐peptide was only detectable at MMTT and not in the fasting state.Conclusions: Stimulated C‐peptide was detectable in an additional 10% of individuals compared with fasting in individuals with >5 years of diabetes duration. T90 and T120 MMTT measurements showed good concordance with the MMTT total AUC. Overall, there was a decrease of C‐peptide at 1‐year follow‐up.


  • Open Access

    Cardiovascular risk management in people with type 1 diabetes: performance using three guidelines

    by Rita Delphine Maiko Varkevisser, Erwin Birnie, Charlotte E Vollenbrock, Dick Mul, Peter R van Dijk, Melanie M van der Klauw, Henk Veeze, Bruce H R Wolffenbuttel, Henk-Jan Aanstoot

    Introduction Cardiovascular disease (CVD) is the leading cause of mortality in individuals with type 1 diabetes mellitus (T1DM). Cardiovascular risk management is therefore essential in the management of individuals with T1DM. This study describes the performance of lipid and blood pressure management in individuals with T1DM using three guidelines. Research design and methods Individuals ≥18 years with T1DM, treated with insulin for ≥1 year, visiting Diabeter or the University Medical Center Groningen between January 1, 2018 and December 31, 2018, were included. Lipid and blood pressure management were examined using the Dutch, American Diabetes Association (ADA) and National Institute for Health and Care Excellence (NICE) guidelines. Concordance of recommended and prescribed lipid-lowering (LLM) or antihypertensive medication (AHM) was assessed per guideline and 10-year age groups. Achievement of treatment targets was assessed for those prescribed medication. Results A total of 1855 individuals with T1DM were included. LLM and AHM was prescribed in 19% and 17%, respectively. In individuals recommended LLM, this was prescribed in 22%–46% according to Dutch, ADA or NICE guideline recommendations. For individuals recommended AHM, this was prescribed in 52%–75%. Recommended and actual prescription of LLM and AHM increased over age for all three guidelines. However, discordance between treatment recommendation and medication prescribed was higher in younger, compared with older, age groups. Low-density lipoprotein-cholesterol targets were achieved by 50% (without CVD) and 31% (with CVD) of those prescribed LLM. The blood pressure target was achieved by 46% of those prescribed AHM. Conclusion This study suggests that there is undertreatment of lipid and blood pressure according to guideline recommendations, particularly in younger age groups. Treatment targets are not met by most individuals prescribed medication, while guidelines recommendations differ considerably. We recommend to investigate the factors influencing undertreatment of lipid and blood pressure management in individuals with T1DM.


  • Open Access

    Genome-wide association study identifies novel loci associated with skin autofluorescence in individuals without diabetes

    by Charlotte E. Vollenbrock, Delnaz Roshandel, Melanie M. van der Klauw, Bruce H.R. Wolffenbuttel, Andrew D. Paterson

    Background Skin autofluorescence (SAF) is a non-invasive measure reflecting accumulation of advanced glycation endproducts (AGEs) in the skin. Higher SAF levels are associated with an increased risk of developing type 2 diabetes and cardiovascular disease. An earlier genome-wide association study (GWAS) revealed a strong association between NAT2 variants and SAF. The aim of this study was to calculate SAF heritability and to identify additional genetic variants associated with SAF through genome-wide association studies (GWAS). Results In 27,534 participants without diabetes the heritability estimate of lnSAF was 33% ± 2.0% (SE) in a model adjusted for covariates. In meta-GWAS for lnSAF five SNPs, on chromosomes 8, 11, 15 and 16 were associated with lnSAF (P < 5 x 10− 8): 1. rs2846707 (Chr11:102576358,C > T), which results in a Met30Val missense variant in MMP27 exon 1 (NM_022122.3); 2. rs2470893 (Chr15:75019449,C > T), in intergenic region between CYP1A1 and CYP1A2; with attenuation of the SNP-effect when coffee consumption was included as a covariate; 3. rs12931267 (Chr16:89818732,C > G) in intron 30 of FANCA and near MC1R; and following conditional analysis 4. rs3764257 (Chr16:89800887,C > G) an intronic variant in ZNF276, 17.8 kb upstream from rs12931267; finally, 30 kb downstream from NAT2 5. rs576201050 (Chr8:18288053,G > A). Conclusions This large meta-GWAS revealed five SNPs at four loci associated with SAF in the non-diabetes population. Further unravelling of the genetic architecture of SAF will help in improving its utility as a tool for screening and early detection of diseases and disease complications.

  • Open Access

    How low is really low? Comparison of two C‐peptide assays to establish residual C‐peptide production in type 1 diabetes

    by Kitty de Leur, Charlotte Vollenbrock, Pim Dekker, Martine de Vries, Erwin Birnie, Dick Mul, Bruce H. R. Wolffenbuttel, Joost Groen, Henk‐Jan Aanstoot, Lianne Boesten

    Introduction: C‐peptide is an important marker to assess residual insulin production in individuals with type 1 diabetes (T1D). The accuracy and detection limits of C‐peptide assays are important to detect C‐peptide microsecretion and to reliably observe changes over time in these people. We compared and verified two commercially available assays able to measure C‐peptide in the picomolar range.Methods: The ultrasensitive Mercodia enzyme‐linked immunosorbent C‐peptide assay (ELISA) was compared with the Beckman immunoradiometric assay (IRMA) for C‐peptide, assessing reproducibility (coefficient of variation [CV]), limit of blank (LoB), limit of detection (LoD) and limit of quantitation (LoQ).Results: For both assays within‐run and between‐run variation were high at the low (around the detection limit) C‐peptide concentration range, with CVs of around 40%. LoB values for the ultrasensitive ELISA and the IRMA were 1.3 and 0.16 pmol/L respectively. LoD values were 2.4 and 0.54 pmol/L respectively. LoQ values were 9.7 and 3.8 pmol/L respectively. Only the IRMA met the specifications claimed by the manufacturer.Conclusions: The IRMA provided the lowest threshold for quantification of serum C‐peptide. LoQ of commercially available assays should be established in‐house before applying them in research studies and clinical trials in which low C‐peptide levels have clinical or scientific relevance.